Deoxycholic Acid Obesity Drugs Market Size to Hit USD 1,830.89 Million by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Deoxycholic Acid Obesity Drugs Market

5.1. COVID-19 Landscape: Deoxycholic Acid Obesity Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Deoxycholic Acid Obesity Drugs Market, By Drug Type

8.1. Deoxycholic Acid Obesity Drugs Market Revenue and Volume, by Drug Type

8.1.1. ATX-101 (Deoxycholic Acid Injection / Kybella / Belkyra)

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Experimental / Compounded Deoxycholic Acid Formulations

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Combination Therapies

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Oral Deoxycholic Acid Products

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Deoxycholic Acid Obesity Drugs Market, By Application

9.1. Deoxycholic Acid Obesity Drugs Market Revenue and Volume, by Application

9.1.1. Submental Fat Reduction

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Abdominal Fat Reduction

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Thighs, Arms, and Flanks

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Lipomas and Localized Fat Deposits

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Cellulite Management

9.1.5.1. Market Revenue and Volume Forecast

Chapter 10. Global Deoxycholic Acid Obesity Drugs Market, By End User

10.1. Deoxycholic Acid Obesity Drugs Market Revenue and Volume, by End User

10.1.1. Aesthetic Clinics & MedSpas

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Dermatology Clinics

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Plastic Surgery Centers

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Hospitals

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Home Administration

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global Deoxycholic Acid Obesity Drugs Market, By Distribution Channel

11.1. Deoxycholic Acid Obesity Drugs Market Revenue and Volume, by Distribution Channel

11.1.1. Physician-Dispensed / In-Clinic Administration

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Deoxycholic Acid Obesity Drugs Market, By Patient Demographics

12.1. Deoxycholic Acid Obesity Drugs Market Revenue and Volume, by Patient Demographics

12.1.1. Adults Aged 25–45 Years

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. 46–60 Years

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Millennials Seeking Non-Surgical Aesthetic Procedures

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Men

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Deoxycholic Acid Obesity Drugs Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Drug Type

13.1.2. Market Revenue and Volume Forecast, by Application

13.1.3. Market Revenue and Volume Forecast, by End User

13.1.4. Market Revenue and Volume Forecast, by Distribution Channel

13.1.5. Market Revenue and Volume Forecast, by Patient Demographics

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Drug Type

13.1.6.2. Market Revenue and Volume Forecast, by Application

13.1.6.3. Market Revenue and Volume Forecast, by End User

13.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6.5. Market Revenue and Volume Forecast, by Patient Demographics

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Drug Type

13.1.7.2. Market Revenue and Volume Forecast, by Application

13.1.7.3. Market Revenue and Volume Forecast, by End User

13.1.7.4. Market Revenue and Volume Forecast, by Distribution Channel

13.1.7.5. Market Revenue and Volume Forecast, by Patient Demographics

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Drug Type

13.2.2. Market Revenue and Volume Forecast, by Application

13.2.3. Market Revenue and Volume Forecast, by End User

13.2.4. Market Revenue and Volume Forecast, by Distribution Channel

13.2.5. Market Revenue and Volume Forecast, by Patient Demographics

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Drug Type

13.2.6.2. Market Revenue and Volume Forecast, by Application

13.2.6.3. Market Revenue and Volume Forecast, by End User

13.2.7. Market Revenue and Volume Forecast, by Distribution Channel

13.2.8. Market Revenue and Volume Forecast, by Patient Demographics

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Drug Type

13.2.9.2. Market Revenue and Volume Forecast, by Application

13.2.9.3. Market Revenue and Volume Forecast, by End User

13.2.10. Market Revenue and Volume Forecast, by Distribution Channel

13.2.11. Market Revenue and Volume Forecast, by Patient Demographics

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Drug Type

13.2.12.2. Market Revenue and Volume Forecast, by Application

13.2.12.3. Market Revenue and Volume Forecast, by End User

13.2.12.4. Market Revenue and Volume Forecast, by Distribution Channel

13.2.13. Market Revenue and Volume Forecast, by Patient Demographics

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Drug Type

13.2.14.2. Market Revenue and Volume Forecast, by Application

13.2.14.3. Market Revenue and Volume Forecast, by End User

13.2.14.4. Market Revenue and Volume Forecast, by Distribution Channel

13.2.15. Market Revenue and Volume Forecast, by Patient Demographics

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Drug Type

13.3.2. Market Revenue and Volume Forecast, by Application

13.3.3. Market Revenue and Volume Forecast, by End User

13.3.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.5. Market Revenue and Volume Forecast, by Patient Demographics

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Drug Type

13.3.6.2. Market Revenue and Volume Forecast, by Application

13.3.6.3. Market Revenue and Volume Forecast, by End User

13.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.7. Market Revenue and Volume Forecast, by Patient Demographics

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Drug Type

13.3.8.2. Market Revenue and Volume Forecast, by Application

13.3.8.3. Market Revenue and Volume Forecast, by End User

13.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.9. Market Revenue and Volume Forecast, by Patient Demographics

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Drug Type

13.3.10.2. Market Revenue and Volume Forecast, by Application

13.3.10.3. Market Revenue and Volume Forecast, by End User

13.3.10.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10.5. Market Revenue and Volume Forecast, by Patient Demographics

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Drug Type

13.3.11.2. Market Revenue and Volume Forecast, by Application

13.3.11.3. Market Revenue and Volume Forecast, by End User

13.3.11.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11.5. Market Revenue and Volume Forecast, by Patient Demographics

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Drug Type

13.4.2. Market Revenue and Volume Forecast, by Application

13.4.3. Market Revenue and Volume Forecast, by End User

13.4.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.5. Market Revenue and Volume Forecast, by Patient Demographics

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Drug Type

13.4.6.2. Market Revenue and Volume Forecast, by Application

13.4.6.3. Market Revenue and Volume Forecast, by End User

13.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.7. Market Revenue and Volume Forecast, by Patient Demographics

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Drug Type

13.4.8.2. Market Revenue and Volume Forecast, by Application

13.4.8.3. Market Revenue and Volume Forecast, by End User

13.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.9. Market Revenue and Volume Forecast, by Patient Demographics

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Drug Type

13.4.10.2. Market Revenue and Volume Forecast, by Application

13.4.10.3. Market Revenue and Volume Forecast, by End User

13.4.10.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10.5. Market Revenue and Volume Forecast, by Patient Demographics

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Drug Type

13.4.11.2. Market Revenue and Volume Forecast, by Application

13.4.11.3. Market Revenue and Volume Forecast, by End User

13.4.11.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11.5. Market Revenue and Volume Forecast, by Patient Demographics

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Drug Type

13.5.2. Market Revenue and Volume Forecast, by Application

13.5.3. Market Revenue and Volume Forecast, by End User

13.5.4. Market Revenue and Volume Forecast, by Distribution Channel

13.5.5. Market Revenue and Volume Forecast, by Patient Demographics

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Drug Type

13.5.6.2. Market Revenue and Volume Forecast, by Application

13.5.6.3. Market Revenue and Volume Forecast, by End User

13.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.5.7. Market Revenue and Volume Forecast, by Patient Demographics

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Drug Type

13.5.8.2. Market Revenue and Volume Forecast, by Application

13.5.8.3. Market Revenue and Volume Forecast, by End User

13.5.8.4. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8.5. Market Revenue and Volume Forecast, by Patient Demographics

Chapter 14. Company Profiles

14.1. AbbVie Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Revance Therapeutics, Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Allergan Aesthetics (subsidiary of AbbVie)

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Revexia Life Sciences

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Sinclair Pharma

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Hyundae Meditech (Korea)

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. DermaSculpt

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Croma Pharma

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Anika Therapeutics

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Revance Therapeutics, Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The deoxycholic acid obesity drugs market size is expected to increase from USD 486.14 million in 2024 to USD 1,830.89 million by 2034.

The deoxycholic acid obesity drugs market is expected to grow at a compound annual growth rate (CAGR) of around 14.18% from 2025 to 2034.

The major players in the deoxycholic acid obesity drugs market include AbbVie Inc., Revance Therapeutics, Inc, Ipsen, Hugel, Inc. (South Korea), Medytox, Inc., Daewoong Pharmaceutical Co., Ltd., Endo International plc, Venus Remedies, Allergan Aesthetics (subsidiary of AbbVie), Revexia Life Sciences, Contura International Ltd., OBE Pharma, NovaBay Pharmaceuticals, Laboratoires VIVACY (France), Sinclair Pharma, Hyundae Meditech (Korea), DermaSculpt, SinoPharm Group, Croma Pharma, and Anika Therapeutics.

Consumer interest in body contouring and non-invasive aesthetic procedures is fueling adoption, especially in urban centers. Expansion of cosmetic clinics and validated long-term efficacy data support growing acceptance.

North America leads the market due to early FDA-approved products and a mature aesthetic infrastructure. Asia Pacific is becoming a high-growth area, driven by rising cosmetic aspirations and emerging clinic presence.